Birger K.
- Country
- Austria
- Department
- Department of Dermatology and Venerology
Research Overview
- Evaluation of Long-Term Safety of Oral Deucrictibant (PHA-022121) for Acute Hereditary Angioedema Attacks in C1-Inhibitor Deficient Patients
- Phase 3 Randomized Double-Blind Placebo-Controlled Crossover Study of Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks in Adolescents and Adults
- A Phase 3 Study to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema
Data & Insights
Has run more than one trial at 25 of 48 partner sites.
Specializations
Angioedema Research
This investigator specializes in the study of hereditary angioedema (HAE), with particular emphasis on innovative therapeutic approaches for managing acute attacks.
- Acute HAE Attack Management
- Type 1 and 2 C1-Inhibitor Deficiency
- On-demand Treatment Development
Their work encompasses both adolescent and adult patient populations affected by HAE.
Treatment Innovation
The investigator focuses on evaluating novel oral therapeutics for acute angioedema attacks, including research into long-term treatment safety profiles.
- Oral Therapeutic Development
- Treatment Safety Assessment
- Symptom Relief Optimization
Their research includes specialized attention to laryngeal attacks management protocols.
Clinical Applications
The investigator's work centers on developing patient-centric treatment solutions for hereditary angioedema management.
- Cross-over Treatment Studies
- Long-term Therapeutic Efficacy
- Emergency Response Protocols
Their research extends to investigating comparative treatment effectiveness through controlled clinical studies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.